SCWorx Announces Resumption of Nasdaq Trading and Highlights Improved Operating Performance and Growth Strategy
Key Highlights
- ➤Nasdaq trading resumed after SCWorx regained listing compliance, subject to a one-year Panel Monitor
- ➤Q2 gross profit rose 83% to approximately $330,000 year over year
- ➤First-half net loss narrowed to approximately $295,000 from approximately $2.4 million
- ➤First-half operating cash use fell to approximately $258,000 from approximately $1.1 million
- ➤September private placement raised gross proceeds of $938,000 in common stock and warrants
Expert Statements
Tim Hannibal, President and Chief Executive Officer of SCWorx
“The resumption of Nasdaq trading is an important milestone for SCWorx and our shareholders, but our focus remains firmly on the underlying business”
Tim Hannibal, President and Chief Executive Officer of SCWorx
“Over the past year, we have significantly improved the economics of the Company while continuing to invest in our technology, healthcare data assets and customer relationships. We believe we are building a more efficient, scalable and strategically valuable healthcare technology company.”
Tim Hannibal, President and Chief Executive Officer of SCWorx
“We believe the strategic value of SCWorx extends beyond an individual software application”
Tim Hannibal, President and Chief Executive Officer of SCWorx
“Over more than a decade, we have developed healthcare-specific data, classification methodologies, attribute structures and institutional knowledge that are embedded in our platform and workflows. Combining these assets with AI-enabled automation creates an opportunity to process healthcare data faster and more efficiently while continuing to maintain the domain expertise and quality controls our customers require.”
Tim Hannibal, President and Chief Executive Officer of SCWorx
“Our goal now is execution”
Tim Hannibal, President and Chief Executive Officer of SCWorx
“We intend to convert the operational improvements we have made into sustainable revenue growth, increased recurring revenue, positive cash flow and long-term shareholder value. We believe SCWorx has valuable healthcare data assets, technology and domain expertise, and our responsibility is to translate those assets into a larger, stronger and more valuable company.”
MIDDLETON, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- SCWorx Corp. (Nasdaq: WORX) ("SCWorx" or the "Company"), a provider of healthcare supply chain data management and analytics solutions, following the resumption of trading of its common stock today on The Nasdaq Capital Market, highlighted the Company's improved operating performance, expanding healthcare customer relationships and continued investment in its proprietary healthcare data and technology platform.
The resumption of Nasdaq trading represents an important milestone for SCWorx and provides the Company with a platform to pursue its next phase of growth following significant improvements in gross profitability and cash utilization during the first half of 2026. As previously announced, on October 2, 2026 the Nasdaq Hearings Panel granted the Company's request for reconsideration of its September 17, 2026 delisting decision, determined that the Company had regained compliance with Nasdaq's continued listing requirements and approved the Company's continued listing on The Nasdaq Capital Market, subject to conditions that include a one-year Panel Monitor. The Panel's decision and its conditions are described in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on October 5, 2026.
Get started
Create a free account to read the full story.